SG11202107272SA - Anti-il2 receptor gamma antigen-binding proteins - Google Patents

Anti-il2 receptor gamma antigen-binding proteins

Info

Publication number
SG11202107272SA
SG11202107272SA SG11202107272SA SG11202107272SA SG11202107272SA SG 11202107272S A SG11202107272S A SG 11202107272SA SG 11202107272S A SG11202107272S A SG 11202107272SA SG 11202107272S A SG11202107272S A SG 11202107272SA SG 11202107272S A SG11202107272S A SG 11202107272SA
Authority
SG
Singapore
Prior art keywords
binding proteins
receptor gamma
gamma antigen
antigen
receptor
Prior art date
Application number
SG11202107272SA
Other languages
English (en)
Inventor
Jamie Orengo
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202107272SA publication Critical patent/SG11202107272SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202107272SA 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins SG11202107272SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799851P 2019-02-01 2019-02-01
PCT/US2020/015841 WO2020160242A1 (en) 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins

Publications (1)

Publication Number Publication Date
SG11202107272SA true SG11202107272SA (en) 2021-07-29

Family

ID=69740681

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107272SA SG11202107272SA (en) 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins

Country Status (15)

Country Link
US (2) US11629195B2 (de)
EP (1) EP3917962A1 (de)
JP (1) JP2022519068A (de)
KR (1) KR20210123350A (de)
CN (1) CN113474370A (de)
AU (1) AU2020214812A1 (de)
BR (1) BR112021014074A2 (de)
CA (1) CA3126117A1 (de)
CL (1) CL2021002008A1 (de)
CO (1) CO2021009693A2 (de)
EA (1) EA202192090A1 (de)
IL (1) IL284579A (de)
MX (1) MX2021008958A (de)
SG (1) SG11202107272SA (de)
WO (1) WO2020160242A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126117A1 (en) * 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
EP4139341A1 (de) * 2020-04-21 2023-03-01 Regeneron Pharmaceuticals, Inc. Il-2-varianten mit reduzierter bindung an il-2-rezeptor-alpha und verwendungen davon
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
CA3236138A1 (en) * 2021-11-02 2023-05-11 Shiyong GONG Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
CN114990206B (zh) * 2022-06-02 2023-04-07 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用
US20240027432A1 (en) 2022-07-13 2024-01-25 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
AU1050697A (en) 1995-11-09 1997-05-29 Dana-Farber Cancer Institute Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
EP0918858A1 (de) * 1996-05-10 1999-06-02 Biogen, Inc. Agenzien, die die gemeinsame gamma-kette blockieren
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
WO2001077288A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
US9469685B2 (en) 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
CN104797601B (zh) 2012-09-12 2019-08-30 建新公司 具有改变的糖基化和降低的效应物功能的包含fc的多肽
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
IL289475B2 (en) 2014-07-21 2023-10-01 Delinia Inc Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases
KR20180037239A (ko) * 2015-08-06 2018-04-11 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Il2r 베타/공통 감마 체인 항체
WO2018156649A1 (en) 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
CA3126117A1 (en) * 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins

Also Published As

Publication number Publication date
MX2021008958A (es) 2021-11-04
CL2021002008A1 (es) 2022-02-04
EA202192090A1 (ru) 2021-10-20
KR20210123350A (ko) 2021-10-13
US11629195B2 (en) 2023-04-18
JP2022519068A (ja) 2022-03-18
EP3917962A1 (de) 2021-12-08
CA3126117A1 (en) 2020-08-06
AU2020214812A1 (en) 2021-09-23
CO2021009693A2 (es) 2021-08-09
US20200247894A1 (en) 2020-08-06
BR112021014074A2 (pt) 2021-11-23
WO2020160242A1 (en) 2020-08-06
CN113474370A (zh) 2021-10-01
IL284579A (en) 2021-08-31
US20230279131A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
IL284579A (en) Antigen-binding proteins against the IL-2 gamma receptor
IL289112A (en) Antibodies against tigit
SG11202108141VA (en) Novel cd40-binding antibodies
IL291068A (en) Anti-cd73 antibodies
IL286100A (en) Formulations of anti-il-36r antibodies
IL284584A (en) Anti-tigit antibodies
IL286147A (en) Bispecific anti-v(beta17)/anti-cd123 antibodies
IL291131A (en) Formulations of anti-il-23p19 antibodies
IL281428A (en) chimeric antigen receptor
ZA202108836B (en) Anti-epha4 antibody
IL279355A (en) Antigen binding protein against STEAP1
EP4083211A4 (de) Anti-cdcp1-antikörper
GB201911187D0 (en) Receptor
GB201905150D0 (en) Ant-ige antibodies
GB201917480D0 (en) Antibodies
GB201910138D0 (en) Anti-pd-l1 antibodies
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201900732D0 (en) Antibodies
GB201807862D0 (en) Chimeric antigen receptor
IL291432A (en) Dosage for anti-tryptase antibodies
IL289160A (en) Anti-angpt2 antibodies
ZA202103350B (en) Anti-igf-i receptor humanized antibody
IL280757A (en) Monoclonal antibodies against human TIM-3
GB201906538D0 (en) Anti-pd-1 antibodies
GB201919280D0 (en) Antibodies